Literature DB >> 2062653

Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element.

T Vickers1, B F Baker, P D Cook, M Zounes, R W Buckheit, J Germany, D J Ecker.   

Abstract

All human immunodeficiency virus mRNAs contain a sequence known as TAR (trans-activating responsive sequence). The TAR element forms a stable RNA stem-loop structure which binds the HIV tat (trans-activator) protein and mediates increased viral gene expression. In principle, molecules which bind to the TAR RNA structure would inhibit trans-activation by perturbing the native RNA secondary structure. We have constructed a series of phosphodiester and phosphorothioate antisense oligonucleotides which specifically bind to the HIV TAR element. Specific binding to the TAR element was demonstrated in vitro with enzymatically synthesized TAR RNA. The TAR-directed phosphorothioates inhibited trans-activation in a sequence-dependent fashion in a cell culture model using an HIV LTR/human placental alkaline phosphatase gene fusion and tat protein supplied in trans. The molecules also inhibited HIV replication in both acute and chronically infected viral assays, but without sequence specificity. We have constructed a series of vectors consisting of the MMTV promoter and 5'-untranslated region of four different mRNAs, including the TAR region, to study the effect of TAR on gene expression in heterologous systems. The results suggest that, in the absence of the HIV LTR, the TAR element has a repressive effect on gene expression, which is relieved by tat.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2062653      PMCID: PMC328335          DOI: 10.1093/nar/19.12.3359

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  46 in total

Review 1.  Tat and Rev: positive regulators of HIV gene expression.

Authors:  C A Rosen; G N Pavlakis
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

Review 2.  HIV TAR: an RNA enhancer?

Authors:  P A Sharp; R A Marciniak
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

3.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner; R Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.

Authors:  J Goodchild; S Agrawal; M P Civeira; P S Sarin; D Sun; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

5.  Induction of chronic human immunodeficiency virus infection is blocked in vitro by a methylphosphonate oligodeoxynucleoside targeted to a U3 enhancer element.

Authors:  J Laurence; S K Sikder; J Kulkosky; P Miller; P O Ts'o
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.

Authors:  B R Cullen
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

7.  Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscopic studies of the Rp-Rp, Sp-Sp, and Rp-Sp duplexes, [d(GGSAATTCC)]2, derived from diastereomeric O-ethyl phosphorothioates.

Authors:  L A LaPlanche; T L James; C Powell; W D Wilson; B Uznanski; W J Stec; M F Summers; G Zon
Journal:  Nucleic Acids Res       Date:  1986-11-25       Impact factor: 16.971

8.  Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.

Authors:  S Agrawal; J Goodchild; M P Civeira; A H Thornton; P S Sarin; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

Authors:  M Matsukura; K Shinozuka; G Zon; H Mitsuya; M Reitz; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

10.  Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues.

Authors:  S Agrawal; T Ikeuchi; D Sun; P S Sarin; A Konopka; J Maizel; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  27 in total

1.  Targeting nucleic acid secondary structures by antisense oligonucleotides designed through in vitro selection.

Authors:  R K Mishra; R Le Tinévez; J J Toulmé
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

2.  Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA.

Authors:  K P Anderson; M C Fox; V Brown-Driver; M J Martin; R F Azad
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 3.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

Review 4.  Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.

Authors:  W Brysch; K H Schlingensiepen
Journal:  Cell Mol Neurobiol       Date:  1994-10       Impact factor: 5.046

5.  Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides.

Authors:  I Demirhan; O Hasselmayer; D Hofmann; A Chandra; F P Svinarchuk; V V Vlassov; J Engels; P Chandra
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

6.  Rational screening of oligonucleotide combinatorial libraries for drug discovery.

Authors:  D J Ecker; T A Vickers; R Hanecak; V Driver; K Anderson
Journal:  Nucleic Acids Res       Date:  1993-04-25       Impact factor: 16.971

7.  Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.

Authors:  J Lisziewicz; D Sun; V Metelev; P Zamecnik; R C Gallo; S Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  3'-modified antisense oligodeoxyribonucleotides complementary to calmodulin mRNA alter behavioral responses in Paramecium.

Authors:  R D Hinrichsen; D Fraga; M W Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

9.  Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region.

Authors:  R F Azad; V B Driver; K Tanaka; R M Crooke; K P Anderson
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity.

Authors:  J Y Tang; J Temsamani; S Agrawal
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.